The histiocytoses: The fall of the Tower of Babel

European Journal of Cancer

Volumn 35, Issue 5, 1999, Pages 747-767

  Arceci, R J ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; BUSULFAN; CHLORMETHINE; CLADRIBINE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; CYTOKINE; DOXORUBICIN; EPIPODOPHYLLOTOXIN; ETOPOSIDE; IBUPROFEN; IMMUNOSUPPRESSIVE AGENT; INDOMETACIN; MERCAPTOPURINE; METHOTREXATE; METHOXSALEN; METHYLPREDNISOLONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; STEROID; THALIDOMIDE; THYMOCYTE ANTIBODY; UNINDEXED DRUG; VINBLASTINE;

CELL LINEAGE; DISEASE CLASSIFICATION; HISTIOCYTOSIS; HISTIOCYTOSIS X; HUMAN; IMMUNE FUNCTION TEST; IMMUNOTHERAPY; NOMENCLATURE; PAIN; PATHOGENESIS; PATHOPHYSIOLOGY; PHOTOTHERAPY; PRIORITY JOURNAL; PUVA; RETICULOENDOTHELIAL SYSTEM; REVIEW; STEM CELL TRANSPLANTATION;

EID: 0032999599     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(99)00039-8     Document Type: Article

References (231)

1. Chu T., D'Angio G.J., Favara B., Ladisch S. Histiocytosis syndromes in children. Lancet. 1:1987;208-209.
2. Henter J.I., Elinder G., Öst Ä. Diagnostic guidelines for hemophagocytic lymphohistiocytosis. Semin. in Oncol. 18:1991;29-33.
3. Cline M.J. Histiocytes and histiocytosis. Blood. 84:1994;2840-2853.
4. Pritchard J., Broadbent V. Histiocytosisan introduction. Br. J. Cancer. 70:1994;S1-S3.
5. Lieberman P.H., Jones C.R., Steinman R.M., et al. Langerhans cell (eosinophilic) granulomatosis. A clinicopathologic study encompassing 50 years. Am. J. Surg. Pathol. 20:1996;519-552.
6. Favara B.E., Feller A.C., Pauli M., et al. Contemporary classification of histiocytic disorders. The WHO Committee On Histiocytic/Reticulum Cell Proliferations. Reclassification Working Group of the Histiocyte Society. Med. Pediat. Oncol. 29:1997;157-166.
7. Gall E.A. The cytochemical identification and interrelation of mesenchymal cells of lymphoid tissue. Ann. NY Acad. Sci. 73:1958;120-123.
8. Aschoff L. Das Reticulo-Endotheliale System. Ergebn. Inn. Med. Kinderhulk. 26:1924;1-118.
9. Craddock CG. Defenses of the body: the initiators of defense, the ready reserves, and the scavengers. In Wintrobe MM, ed. Blood, Pure and Eloquent. New York, McGraw-Hill, 1980, 417-454.
10. Van Furth R. Origin and kinetics of monocytes and macrophages. Semin. Hemat. 7:1970;125-141.
11. Langerhans P. Über die Nerven der menschlichen Haut. Virchows Arch. Pathol. Anat. 44:1868;325.
12. Langerhans P. Berichtigungen. Archiv. Mikroskopische. Anatomie. 20:1882;641.
13. Silberberg I., Baer R.L., Rosenthal S.A. The role of Langerhans cells in contact allergy. I. An ultrastructural study in actively induced contact dermatitis in guinea pigs. Acta Dermato-Venereologica. 54:1974;321-331.
14. Steinman R., Inaba K. Immunogenicity: role of dendritic cells. BioEssays. 10:1989;145-152.
15. Tavassoli M. Bone marrow: the seedbed of blood. In Wintrobe MM, ed. Blood, Pure and Eloquent. New York, McGraw-Hill, 1980, 57-79.
16. Dieterlen-Lievre F., Godin I., Garcia-Porrero J., Marcos M. Initiation of hemopoiesis in the mouse embryo. Ann. NY Acad. Sci. 718:1994;140-146.
17. Godin I.E., Garcia-Porrero J.A., Coutinho A., Dieterlen-Lievre F., Marcos M.A. Para-aortic splanchnopleura from early mouse embryos contains B1 a cell progenitors. Nature. 364:1993;67-70.
18. Medvinsky A., Dzierzak E. Definitive hematopoiesis is autonomously initiated by the AGM region. Cell. 86:1996;897-906.
19. Ohneda O., Fennie C., Zheng Z., et al. Hematopoietic stem cell maintenance and differentiation are supported by embryonic aorta-gonad-mesonephros region-derived endothelium. Blood. 92:1998;908-919.
20. Lajtha LG. The common ancestral cell. In Wintrobe MM, ed. Blood, Pure and Eloquent. New York, McGraw-Hill, 1980, 81-95.
21. Schmitz L., Favara B.E. Nosology and pathology of langerhans cell histiocytosis. Hemat./Oncol. Clin. North Am. 12:1998;221-246.
22. Hart D.N.J. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood. 90:1997;3245-3287.
23. Thomas R., Lipsky P.E. Dendritic cells: origin and differentiation. Stem cells. 14:1996;196-206.
24. Rosenzwajg M., Canque B., Gluckman J.C. Human dendritic cell differentiation pathway from CD334+ hematopoiettic precursor cells. Blood. 87:1996;535-544.
25. Ryncarz R., Anasetti C. Expression of CD86 on human marrow CD34+ cells identifies immunocompetent committed precursors of macrophages and dendritic cells. Blood. 91:1998;3892-3900.
26. Mackensen A., Herbst B., Kohler G., et al. Delineation of the dendritic cell lineage by generating large numbers of Birbeck granule-positive Langerhans cells from human peripheral blood progenitor cells in vitro. Blood. 86:1995;2699-2707.
27. Ishii E, Watanabe S. Biochemistry and biology of the Langerhans cell. In Osband ME, Pochedly C, eds. Hemat Oncol Clin North Am 1. Philadelphia, W.B. Saunders, 1987, 99-118.
28. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature. 392:1998;245-252.
29. Arceci R. Histiocytoses and disorders of the reticuloendothelial system. In Handin RI, Lux SE, Stossel TP, eds. Blood: Principles and Practice of Hematology. Philadelphia, J.B. Lippincott, 1995, 915-946
30. Favara B.E., Jaffe R. The histopathology of Langerhans cell histiocytosis. Br. J. Cancer. 23:(Suppl.):1994;17-23.
31. Egeler R.M., D'Angio G.J. Langerhans cell histiocytosis. J. Pediat. 127:1995;1-11.
32. Lampert F. Langerhans cell histiocytosis: historical perspectives. Hemat. Oncol. Clin. North Am. 12:1998;213-219.
33. Hand A.J. Polyuria and tuberculosis. Arch. Pediat. 10:1893;673.
34. Schüller A. Über eigenartige Schädeldefekte im Jugendalter. Fortschrifte Roentgenstrahlen. 23:1915;12.
35. Christian H.A. Defects in membranous bones, exophthalmos and diabetes insipidus; an unusual syndrome of dyspituitarism. Med. Clin. North Am. 3:1919;849.
36. Letterer E. Aleukämische Retikulose (Ein Beitrag zu den proliferativen Erkankungen des Retikuloendothelialapparates. Frankfurter Zeitschrift für Pathologie. 30:1924;377.
37. Siwe S.A. Die Reticuloendothelioseein neues Krankheitsbild unter den Hepatosplenomegalien. Z. Kinderheilk. 55:1933;212.
38. Farber S. The nature of "solitary or eosiniphilic granuloma" of bone. Am. J. Pathol. 17:1941;625.
39. Lichtenstein L. Histiocytosis X: integration of eosiniphilic granuloma of the bone, Letterer-Siwe disease and Schuller-Christian disease as related manifestations of a single nosologic entity. Arch. Pathol. 56:1953;84.
40. Nezelof C., Basset F., Rousseau M.F. Histiocytosis X: histogenetic arguments for a Langerhans cell origin. Biomedicine. 18:1973;365-371.
41. Farquhar J., Clairveaux A. Familial haemophagocytic reticulosis. Arch. Dis. Child. 27:1952;519.
42. Nelson P., Santamaria A., Olson R., et al. Generalized lymphohistiocytic infiltration. A familial disease not previously described and different from Letterer-Siwe and Chédiak-Higashi syndrome. Pediatrics. 27:1961;931.
43. MacMahon H.E., Bedizel M., Ellis C. Familial erythrophagocytic lymphohistiocytosis. Pediatrics. 32:1963;868.
44. Nezelhof C., Elizchar E. Familial lymphohistiocytosis: a report of three cases with general review. Possible links with secondary syndromes. Nouvelle Revue Francaise d'Hematologie. 13:1973;319-337.
45. Miller D. Familial reticuloendotheliosis: concurrence of disease in five siblings. Pediatrics. 38:1966;968-995.
46. Ladisch S., Ho W., Matheson D. Immunologic and clinical effects of repeated blood exchange in familial erythrophagocytic lymphohistiocytosis. Blood. 60:1982;814.
47. Janka G.E. Familial hemophagocytic lymphohistiocytosis. Eur. J. Pediat. 140:1983;221-230.
48. Henter J-I., Aricò M., Elinder G., Imashuku S., Janka G. Familial hemophagocytic lymphohistiocytosis. Hemat. Oncol. Clin. North Am. 12:1998;417-433.
49. Janka G., Imashuku S., Elinder G., Schneider M., Henter J-I. Infection- and malignancy-associated hemophagocytic syndromes. Hemat. Oncol. Clin. North Am. 12:1998;435-444.
50. Carstensen H., Ornvold K. The epidemiology of LCH in children in Denmark, 1975-89. Med. Pediat. Oncol. 21:1993;387-388.
51. Kaatsch P, Maaf HG, Michalis J. Jahresbericht 1993 des Deutschen Kinderkrebregisters (vol 6) 6. Mainz, IMSD Johannes Gutenberg, Universitat Institut fur Medizinishe Statistik und Dokumentation, 1994, 14-15.
52. Nicholson HS, Egeler RM, Nesbit ME. The epidemiology of Langerhans cell histiocytosis. In Egeler RM, D'Angio GJ, eds. Hematology/Oncology Clinics of North America 12. Philadelphia, W.B. Saunders, 1998, 379-384.
53. Hamre M., Hedberg J., Buckley J., et al. Langerhans cell histiocytosis: an exploratory epidemiologic study of 177 cases. Med. Pediat. Oncol. 28:1997;92-97.
54. Bhatia S., Nesbit M.E. Jr., Egeler R.M., Buckley J.D., Mertens A., Robison L.L. Epidemiologic study of Langerhans cell histiocytosis in children. J. Pediat. 130:1997;774-784.
55. Egeler R.M., Neglia J.P., Puccetti D.M., Brennan C.A., Nesbit M.E. Association of Langerhans cell histiocytosis with malignant neoplasms. Cancer. 71:1993;865-873.
56. Egeler RM, Neglia JP, Arico M, et al. The relation of Langerhans cell histiocytosis to acute leukemia, lymphomas, and other solid tumors. The LCH-Malignancy Study Group of the Histiocyte Society. In Egeler RM, D'Angio GJ, eds. Hematology/Oncology Clinics of North America 12. Philadelphia. W.B. Saunders, 1998, 369-378.
57. Horibe K., Matsushita T., Numata S., et al. Acute promyelocytic leukemia with t(15;17) abnormality after chemotherapy containing etoposide for Langerhans cell histiocytosis. Cancer. 72:1993;3723-3726.
58. Kanold J., Vannier J.P., Fusade T., et al. Langerhans cell histiocytosis in twin sisters. Arch. Pediatrie. 1:1994;49-53.
59. Halton J., Whitton A., Wiernikowski J., Barr R.D. Disseminated Langerhans cell histiocytosis in identical twins unresponsive to recombinant human alpha-interferon and total body irradiation. Am. J. Pediat. Hemat-Oncol. 14:1992;269-272.
60. Katz A.M., Rosenthal D., Jakubovic H.R., Pai R.K., Quinonez G.E., Sauder D.N. Langerhans cell histiocytosis in monozygotic twins. J. Am. Acad. Dermat. 24:1991;32-37.
61. Kuwabara S., Takahashi M. Eosinophilic granuloma of the skull in identical twinscase report. Neurol. Med. Chir. Tokyo. 30:1990;1043-1046.
62. Caldarini G. Remarks on a case of Letterer-Siwe disease in a pair of twins. Clin. Pediat. Bologna. 48:1966;315-332.
63. Freundlich E., Amit S., Montag Y., Suprun H., Nevo S. Familial occurrence of Letterer-Siwe disease. Arch. Dis. Child. 1972:1972;122-125.
64. Mader I., Stock K.W., Radue E.W., Steinbrich W. Langerhans cell histiocytosis in monozygotic twins: case reports. Neuroradiology. 38:1996;163-165.
65. Arico M., Arceci R., Haupt R., et al. Familial recurrence of Langerhans cell histiocytosis (LCH). Blood. 92:1998;536a.
66. de Chadarevian J-P., Pawel B. Hereditary Langerhans cell histiocytosis: instances of apparent vertical transmission. Med. Pediat. Oncol. 31:1998;559.
67. Bayar E., Kurczynski T.W., Robinson M.G., Tyrkus M., al Saadi A. Monozygotic twins with congenital acute lymphoblastic leukemia (ALL) and t(4;11)(q21;q23). Cancer Genet. Cytogenet. 89:1996;177-180.
68. Mahmoud H., Ridge S.A., Behm F.G., et al. Intrauterine monoclonal origin of neonatal concordant acute lymphoblastic leukemia in monozygotic twins. Med. Pediat. Oncol. 24:1995;77-81.
69. Ford A.M., Bennett C.A., Price C.M., Bruin M.C., Van Wering E.R., Greaves M. Fetal origins of the TEL-AML1 fusion gene in identical twins with leukemia. Proc. Natl. Acad. Sci. U.S.A. 95:1998;4584-4588.
70. Megonigal M.D., Rappaport E.F., Jones D.H., et al. t(11;22)(q23;q11.2) In acute myeloid leukemia of infant twins fuses MLL with hCDCrel, a cell division cycle gene in the genomic region of deletion in DiGeorge and velocardiofacial syndromes. Proc. Natl. Acad. Sci. USA. 95:1998;6413-6418.
71. Knudsen A.G. Jr. Hereditary cancer, oncogenes, and antioncogenes. Cancer. 45:1985;1437-1443.
72. Egeler RM. Genetic predisposition in Langerhans cell histiocytosis? An hypothesis (Ph.D. Thesis). In Haveka BV, ed. Langerhans Cell Histiocytosis and Other Histiocytic Disorders. The Netherlands, University of Amsterdam, 1993, 181-197.
73. Willman C.L., Busque L., Griffith B.B., et al. Langerhans'-cell histiocytosis (histiocytosis X)a clonal proliferative disease. N. Eng. J. Med. 331:1994;154-160.
74. Willman C.L. Detection of clonal histiocytes in Langerhans cell histiocytosis: biology and clinical significance. Br. J. Cancer. 23:1994;29-33.
75. Yu R.C., Chu A., Buluwela L., Chu R. Clonal proliferation of Langerhans cells in Langerhans cell histiocytosis. Lancet. 343:1994;767-768.
76. Yu R.C., Chu A.C. Lack of T-cell receptor gene rearrangements in cells involved in Langerhans cell histiocytosis. Cancer. 75:1995;1162-1166.
77. Willman CL, McClain KL. An update on clonality, cytokines, and viral etiology in Langerhans cell histiocytosis. In Egeler RM, D'Angio GJ, eds. Hemat/Oncol Clin North Am 12. Philadelphia, W.B. Saunders, 1998, 407-416.
78. Paulli M, Bergamaschi G, Tonon L, et al. Evidence for a polyclonal nature of the cell infiltrate in sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease). Br J Haematol 91, 415-418.
79. Weiss L.M., Wood G.S., Trela M. Clonal T cell populations in lymphomatoid papulosis: evidence of a lymphoproliferative origin for a clinically benign disease. N Engl J Med. 315:1986;475-479.
80. Kurahashi H., Hara J., Yumura-Yagi K. Monoclonal nature of transient abnormal myelopoiesis in Down's syndrome. Blood. 77:1991;1161-1163.
81. McLelland J., Newton J., Malone M. A flow cytometric study of Langerhans cell histiocytosis. Br. J. Dermatol. 120:1989;485-491.
82. Ornvold K., Carstensen H., Larsen J.K., Christensen I.J., Ralfkiaer E. Flow cytometric DNA analysis of lesions from 18 children with Langerhans cells histiocytosis (histiocytosis X). Am. J. Pathol. 136:1990;1304-1307.
83. Frost J.D., Wiersma S.R. Progressive Langerhans cell histiocytosis in an infant with Klinefelter syndrome successfully treated with allogeneic bone marrow transplantation. J. Pediat. Hemat. Oncol. 18:1996;396-400.
84. Betts D.R., Leibundgut K.E., Feldges A., Pluss H.J., Niggli F.K. Cytogenetic abnormalities in Langerhans cell histiocytosis. Cancer. 77:1998;552-555.
85. Golub T., Barker G., Lovett M., Gilliland D. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell. 77:1994;307-316.
86. Golub T. TEL gene rearrangements in myeloid malignancy. Hemat. Oncol. Clin. North Am. 11:1997;1207-1220.
87. Kobayashi H., Satake N., Kaneko Y. Detection of the Der (21)t(12;21) chromosome forming the TEL-AML1 fusion gene in childhood acute lymphoblastic leukemia. Leuk. Lymphoma. 28:1997;43-50.
88. Amor D., Algar E., Slater H., Smith P. High frequency of t(12;21) in childhood acute lymphoblastic leukemia detected by RT-PCR. Pathology. 30:1998;381-385.
89. Loh M., Silverman L., Young M., et al. Incidence of TEL/AML1 fusion in children with relapsed acute lymphoblastic leukemia. Blood. 92:1998;4792-4797.
90. Haag MM, Avet-Loiseau H, Favara B, et al. Evaluation of a series of cases of Langerhans cell histiocytosis by comparative genomic hybridization, 6th Int Workshop on Chromosomes in Solid Tumors February, Tucson, Arizona, 1991.
91. Chu T., Jaffe R. The normal Langerhans cell and the LCH cell. Br. J. CancerSupplement. 23:1994;4-10.
92. McLelland J., Chu A.C. Comparison of peanut agglutinin and S100 stain in the paraffin tissue diagnosis of Langerhans cell histiocytosis. Br. J. Dermatol. 119:1988;513-521.
93. Hage C., Willman C.L., Favara B.E., Isaacson P.G. Langerhans' cell histiocytosis (histiocytosis X): immunophenotype and growth fraction. Hum. Pathol. 24:1993;840-845.
94. Kannourakis G., Abbas A. The role of cytokines in the pathogenesis of Langerhans cell histiocytosis. Br. J. Cancer. 23:1994;S37-S40.
95. Emile J.F., Fraitag S., Andry P., Leborgne M., Lellouch-Tubiana A., Brousse N. Expression of GM-CSF receptor by Langerhans' cell histiocytosis cells. Virchows Archiv. 427:1995;125-129.
96. Foss H.D., Herbst H., Araujo I., et al. Monokine expression in Langerhans' cell histiocytosis and sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease). J. Pathol. 179:1996;60-65.
97. Arenzana-Seisdedos F., Barbey S., Virelizier J.L., Kornprobst M., Nezelof C. Histiocytosis X. Purified (T6+) cells from bone granuloma produce interleukin 1 and prostaglandin E2 in culture. J. Clin. Invest. 77:1986;326-329.
98. Henter J.I., Andersson B., Elinder G., Jakobson A., Lubeck P.O., Soder O. Elevated circulating levels of interleukin-1 receptor antagonist but not IL-1 agonists in hemophagocytic lymphohistiocytosis. Med. Pediat. Oncol. 27:1996;21-25.
99. Osugi Y., Hara J., Tagawa S., et al. Cytokine production regulating Th1 and Th2 cytokines in hemophagocytic lymphohistiocytosis. Blood. 89:1997;4100-4103.
100. Newton Jr W.A., Hamoudi A.B., Shannon B.T. Role of the thymus in histiocytosis-X. Hemat. Oncol. Clin. North Am, 1:1987;63-74.
101. Osband M.E., Lipton J.M., Lavin P., et al. Histiocytosis-X. N. Engl. J. Med. 304:1981;146-153.
102. Henter J.-I., Elinder G., Soder O., Ost A. Incidence and clinical features of familial hemophagocytic lymphohistiocytosis in Sweden. Acta. Paediat. Scand. 80:1991;428-435.
103. Stark B., Hershko C., Rosen N., Cividalli G., Karsai H., Soffer D. Familial hemophagocytic lymphohistiocytosis (FHLH) in Israel. I. Description of 11 patients of Iranian-Iraqi origin and review of the literature. Cancer. 54:1984;2109-2121.
104. Arico M., Janka G., Fischer A., et al. Hemophagocytic lymphohistiocytosis. Report of 122 children from the International Registry. FHL Study Group of the Histiocyte Society. Leukemia. 10:1996;197-203.
105. Hirst W., Layton D., Singh S., et al. Haemophagocytic lymphohistiocytosis: experience at two U.K. Centres. Br. J. Haemat. 88:1994;731-739.
106. Tsudo M., Moriguchi T., Nakayama H., Tazawa H., Inoue M., Kawa-Ha K. Chronic active EB virus infection accompanied by monoclonal proliferation of granular lymphocytes. Rinsho KetsuekiJpn. J. Clin. Hematol. 36:1995;218-223.
107. Kaneko Y., Maseki N., Sakurai M., et al. Clonal and non-clonal karyotypically abnormal cells in haemo-phagocytic lymphohistiocytosis. Br. J. Haematol. 90:1995;48-55.
108. Kawaguchi H., Miyashita T., Herbst H., et al. Epstein-Barr virus-infected T-lymphocytes in Epstein-Barr virus-associated hemophagocytic syndrome. J. Clin. Invest. 92:1993;1444-1450.
109. Imashuku S, Hibi S, Tabata Y, et al. Outcome of clonal hemophagocytic lymphohistiocytosis: analysis of 34 cases. Fourteenth Annual Meeting of the Histiocyte Society, Kyoto, Japan, 1998, 38.
110. Hansmann M.L., Rontogianni D., Janka-Schaub G.E., Wacker H.H., Hinkeldey K., Radzun H.J. Familial hemophagocytic lymphohistiocytosis. Macrophages showing immunohistochemical properties of activated macrophages and T-accessory cells. J. Pediat. Hemat. Oncol. 6:1989;237-246.
111. Egeler R.M., Shapiro R., Loechelt B., Filipovich A. Characteristic immune abnormalities in hemophagocytic lymphohistiocytosis. J. Pediat. Hemat. Oncol. 18:1996;340-345.
112. Kataoka Y., Todo S., Morioka Y., et al. Impaired natural killer activity and expression of interleukin-2 receptor antigen in familial erythrophagocytic lymphohistiocytosis. Cancer. 65:1990;1937-1941.
113. Sullivan K.E., DeLaat C., Douglas S.D., Filipovich A.H. Defective natural killer cell function in patients with hemophagocytic lymphohistiocytosis and in first degree relatives. Pediat. Res. 44:1998;465-468.
114. Rieux-Laucat F., Le Deist F., Hivroz C. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science. 268:1995;1247-1349.
115. Le Deist F., Emile J., Rieux-Laucat F., et al. Clinical, immunological, and pathological consequences of Fas-deficient conditions. Lancet. 348:1996;719-723.
116. Drappa J., Vaishnaw A., Sullivan K., Chu J., Elkon K. Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity. N. Engl. J. Med. 335:1996;1643-1649.
117. Dianzani U., Bragardo M., DiFranco D., et al. Deficiency of the Fas apoptosis pathway without Fas gene mutations in pediatric patients with autoimmunity/lymphoproliferation. Blood. 89:1997;2871-2879.
118. Favara B.E. Hemophagocytic lymphohistiocytosis: a hemophagocytic syndrome. Semin. Diagnostic Pathol. 9:1992;63-74.
119. Goldberg J., Nezelof C. Lymphohistiocytosis: a multi-factorial syndrome of macrophagic activation clinico-pathological study of 38 cases. Hemat. Oncol. 4:1986;275-289.
120. Bejaoui M., Veber F., Girault D., et al. The accelerated phase of Chediak-Higashi syndrome. Arch. Fr. Pediatr. 46:1989;733-736.
121. Imashuku S., Hibi S., Sako M., et al. Heterogeneity of immune markers in hemophagocytic lymphohistiocytosis: comparative study of 9 familial and 14 familial inheritance-unproved cases. J. Pediat. Hemat./Oncol. 20:1998;207-214.
122. Ohga S., Matsuzaki A., Nishizaki M., et al. Inflammatory cytokines in virus-associated hemophagocytic syndrome. Am. J. Pediat. Hematol. Oncol. 15:1993;291-298.
123. Henter J-I. Hypercytokinemia in familial hemophagocytic lymphohistiocytosis. Blood. 1991:1991;1918-2922.
124. Imashuku S., Hibi S. Cytokines in haemophagocytic syndrome. Br. J. Haematol. 77:1991;438-440.
125. Komp D.M., McNamara J., Buckley P. Elevated soluble interleukin-2 receptor in childhood hemophagocytic histiocytic syndromes. Blood. 73:1989;2128-2132.
126. Trinchieri G., Gerosa F. Immunoregulation by interleukin-12. J. Leuk. Biol. 59:1996;505-511.
127. Kennedy M.K., Picha K.S., Shanebeck K.D., Anderson D.M., Grabstein K.H. Interleukin-12 regulates the proliferation of Th 1, but not Th2 or Th0 clones. Eur. J. Immunol. 24:1994;2271-2278.
128. Tzortzatou-Stathopoulou F., Xaidara A., Mikraki V., et al. Effect of trimethoprim-sulphamethoxazole in Langerhans' cell histiocytosis: preliminary observations. Med. Pediat. Oncol. 25:1995;74-78.
129. Komp DM. Historical perspectives of Langerhans cell histiocytosis. In Osband ME, Pochedly C, eds. Hemat/Oncol Clin North Am 1. Philadelphia, W.B. Saunders, 1987, 9-21.
130. Ladisch S., Gadner H. Treatment of Langerhans cell histiocytosisevolution and current approaches. Br. J. Cancer. 23:(Suppl.):1994;S41-46.
131. Broadbent V, Gadner H. Current therapy for Langerhans cell histiocytosis. In Egeler RM, D'Angio GJ, eds. Hemat/Oncol Clin North Am 12. Philadelphia, W.B. Saunders, 1998, 327-338.
132. Arceci RJ, Brenner MK, Pritchard J. Controversies and new approaches to treatment of Langerhans cell histiocytosis. In Egeler RM, D'Angio GJ, eds. Hemat/Oncol Clin North Am 12. Philadelphia, W.B. Saunders, 1998, 339-357.
133. McLean T.W., Pritchard J. Langerhans cell histiocytosis and hypercalcemia: clinical response to indomethacin. J. Pediat. Hemat./Oncol. 18:1996;318-320.
134. Wirtschafter J.D., Nesbit M., Anderson P., McClain K. Intralesional methylprednisolone for Langerhans' cell histiocytosis of the orbit and cranium. J. Pediat. Ophthalmol. Strabismus. 24:1987;194-197.
135. Egeler R.M., Thompson R.C. Jr., Voute P.A., Nesbit M.E. Jr. Intralesional infiltration of corticosteroids in localized Langerhans' cell histiocytosis. J. Pediat. Orthopedics. 12:1992;811-814.
136. Greenberger J.S., Cassady J.R., Jaffe N., Vawter G., Crocker A.C. Radiation therapy in patients with histiocytosis: management of diabetes insipidus and bone lesions. Int. J. Radiat. Oncol. Biol. Phys. 5:1979;1749-1755.
137. Greenberger J.S., Crocker A.C., Vawter G., Jaffe N., Cassady J.R. Results of treatment of 127 patients with systemic histiocytosis (Letterer-Siwe syndrome, Schuller-Christian syndrome and multifocal eosinophilic granuloma). Medicine. 60:1981;311-338.
138. Gramatovici R., D'Angio G.J. Radiation therapy in soft-tissue lesions in histiocytosis X (Langerhans' cell histiocytosis). Med. Pediat. Oncol. 16:1988;259-262.
139. Lipton J.M. The pathogenesis, diagnosis and treatment of histiocytosis syndromes. Pediat. Dermatol. 1:1983;112-120.
140. Sheehan M.P., Atherton D.J., Broadbent V., Pritchard J. Topical nitrogen mustard: an effective treatment for cutaneous Langerhans cell histiocytosis. J. Pediat. 119:1991;317-321.
141. Iwatsuki K., Tsugiki M., Yoshizawa N., Takigawa M., Yamada M., Shamoto M. The effect of phototherapies on cutaneous lesions of histiocytosis-X in the elderly. Cancer. 57:1986;1931-1936.
142. Sakai H., Ibe M., Takahashi H., et al. Satisfactory remission achieved by PUVA therapy in Langerhans cell histiocytosis in an elderly patient. J. Dermatol. 23:1996;42-46.
143. Munn S, Chu AC. Langerhans cell histiocytosis of the skin. In Egeler RM, D'Angio GJ, eds. Langerhans Cell Histiocytosis 12. Philadelphia, W.B. Saunders, 1998, 269-286.
144. Lahey M.E. Histiocytosis Xcomparison of three treatment regimens. J. Pediatr. 87:1975;179-183.
145. Lahey M.E. Prognostic factors in histiocytosis X. Am. J. Pediat. Hemat./Oncol. 3:1981;57-60.
146. Ceci A., de Terlizzi M., Colella R., et al. Langerhans cell histiocytosis in childhood: results from the Italian Cooperative AIEOP-CNR-H.X '83 study. Med. Pediat. Oncol. 21:1993;259-264.
147. Gadner H., Heitger A., Ritter J., et al. Langerhans cell histiocytosis in childhoodresults of the DAL-HX 83 study. Klinische. Padiatrie. 199:1987;173-182.
148. Grois N., Flucher-Wolfram B., Heitger A., Mostbeck G.H., Hofmann J., Gadner H. Diabetes insipidus in Langerhans cell histiocytosis: results from the DAL-HX 83 study. Med. Pediat. Oncol. 24:1995;248-256.
149. McLelland J., Broadbent V., Yeomans E., Malone M., Pritchard J. Langerhans cell histiocytosis: the case for conservative treatment. Arch. Dis. Childhood. 65:1990;301-303.
150. Filocoma D., Needleman H.L., Arceci R., Gelber R.D., Donnelly M. Pediatric histiocytosis. Characterization, prognosis, and oral involvement. Am. J. Pediat. Hemat./Oncol. 15:1993;226-230.
151. Rosenzweig K.E., Arceci R.J., Tarbell N.J. Diabetes insipidus secondary to Langerhans' cell histiocytosis: is radiation therapy indicated? Med. Pediat. Oncol. 29:1997;36-40.
152. Ladisch S., Gadner H., Arico M., et al. LCH-I: a randomized trial of etoposide vs vinblastine in disseminated Langerhans cell histiocytosis. The Histiocyte Society. Med. Ped. Oncol. 23:1994;107-110.
153. Larson R.A., Mick R., Spielberger R.T., O'Brien S.M., Ratain M.J. Dose-escalation trial of cladribine using five daily intravenous infusions in patients with advanced hematologic malignancies. J. Clin. Oncol. 14:1996;188-195.
154. McCowage G.B., Frush D.P., Kurtzberg J. Successful treatment of two children with Langerhans' cell histiocytosis with 2'-deoxycoformycin. J. Pediat. Hemat. Oncol. 18:1996;154-158.
155. Saven A., Figueroa M.L., Piro L.D., Rosenblatt J.D. 2-Chlorodeoxyadenosine to treat refractory histiocytosis X. N. Eng. J. Med. 329:1993;734-735.
156. Wayne A.S., Tan C.T.C., Arceci R.J., et al. 2-Chlorodeoxyadenosine (2CDA) for disorders of mono-histiocytic lineage. Blood. 84:1994;57a.
157. Petersen A.J., Brown R.D., Gibson J., et al. Nucleoside transporters, bcl-2 and apoptosis in CLL cells exposed to nucleoside analogues in vitro. Eur. J. Haematol. 56:1996;213-220.
158. Lauria F. 2-Chlorodeoxyadenosine, a "novel" agent in the treatment of both lymphoid and myeloid malignancies. Haematologica. 77:1992;443-445.
159. Gandhi V., Estey E., Keating M.J., Chucrallah A., Plunkett W. Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions. Blood. 87:1996;256-264.
160. 2-receptor deficiency, and successful treatment with thymic extract. N. Engl. J. Med. 304:1981;146-153.
161. Ceci A., de Terlizzi M., Toma M.G., et al. Heterogeneity of immunological patterns in Langerhan's histiocytosis and response to crude calf thymic extract in 11 patients. Med. Pediat. Oncol. 16:1988;111-115.
162. Ceci A., de Terlizzi M., Colella R., et al. Langerhans cell histiocytosis in childhood: results from the Italian Cooperative AIEOP-CNR-H.X '83 study. Med. Pediat. Oncol. 21:1993;259-264.
163. Hirose M., Saito S., Yoshimoto T., Kuroda Y. Interleukin-2 therapy of Langerhans cell histiocytosis. Acta. Paediatrica. 84:1995;1204-1206.
164. Mahmoud H.H., Wang W.C., Murphy S.B. Cyclosporine therapy for advanced Langerhans cell histiocytosis. Blood. 77:1991;721-725.
165. Arico M., Colella R., Conter V., et al. Cyclosporine therapy for refractory Langerhans cell histiocytosis. Med. Pediat. Oncol. 25:1995;12-16.
166. Jakobson A.M., Kreuger A., Hagberg H., Sundstrom C. Treatment of Langerhans cell histiocytosis with alpha-interferon. Lancet. 2:1987;1520.
167. Albanell J., Salud A., Bellmunt J., et al. Treatment with interferon of systemic Langerhans-cell histiocytosis in an adult. Medicina. Clinica. 94:1990;184-186.
168. Sato Y., Ikeda Y., Ito E., et al. Histiocytosis X: successful treatment with recombinant interferon-alpha A. Acta Paediat. Japonica. 32:1990;151-154.
169. Misery L., Larbre B., Lyonnet S., Faure M., Thivolet J. Remission of Langerhans cell histiocytosis with thalidomide treatment. Clin. Exp. Dermatol. 18:1993;487.
170. Thomas L., Ducros B., Secchi T., Balme B., Moulin G. Successful treatment of adult's Langerhans cell histiocytosis with thalidomide. Report of two cases and literature review. Arch. Dermatol. 129:1993;1261-1264.
171. Meunier L., Marck Y., Ribeyre C., Meynadier J. Adult cutaneous Langerhans cell histiocytosis: remission with thalidomide treatment. Br. J. Dermatol. 132:1995;168.
172. Ringden O., Ahstrom L., Lonnqvist B. Allogeneic bone marrow transplantation in a patient with chemotherapy-resistant progressive histiocytosis X. N. Engl. J. Med. 316:1987;733-735.
173. Stoll M., Freund M., Schmid H. Allogeneic bone marrow transplantation for Langerhans' cell histiocytosis. Cancer. 66:1990;284.
174. Dehner L.P. Allogeneic bone marrow transplantation in a patient with chemotherapy resistant progressive histiocytosis X. N. Engl. J. Med. 317:1987;773.
175. Conter V., Reciputo A., Arrigo C., Bozzato N., Sala A., Arico M. Bone marrow transplantation for refractory Langerhans' cell histiocytosis. Haematologica. 81:1996;468-471.
176. Anonymous. A multicentre retrospective survey of Langerhans' cell histiocytosis: 348 cases observed between 1983 and 1993. The French Langerhans' Cell Histiocytosis Study Group. Arch Dis Childhood 1996, 75, 17-24.
177. Morgan G. Myeloablative therapy and bone marrow transplantation for Langerhans' cell histiocytosis. Br. J. Cancer. 23:1994;S52-S53.
178. Brenner M.K. The contribution of marker gene studies to hemopoietic stem cell therapies. Stem Cells. 13:1995;453-461.
179. Brenner M.K. Genetic marking and manipulation of hematopoietic progenitor cells using retroviral vectors. Immunomethods. 5:1994;204-210.
180. Brenner M.K., Rill D.R., Moen R.C., et al. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet. 341:1993;85-86.
181. Fearnley D., Whyte L., Carnoutsos S., Cook A., Hart D. Monitoring human blood dendritic cell numbers in normal individuals and in stem cell transplantation. Blood. 93:1998;728-736.
182. Arceci R.J. Treatment optionscommentary. Br. J. Cancer. 23:(Suppl.):1994;58-60.
183. Soua H., Pousse H., Ladeb F., et al. Histiocytosis X and sclerosing cholangitis. Annales. Pediatrie. 40:1993;316-319.
184. Neveu I., Labrune P., Huguet P., Musset D., Chaussain J.L., Odievre M. Sclerosing cholangitis revealing histiocytosis X. Arch. Francaises Pediatrie. 47:1990;197-199.
185. Puel O., Guillard J.M. Sclerosing cholangitis in the course of histiocytosis X. Arch. Francaises Pediatrie. 47:1990;155-156.
186. Thompson H.H., Pitt H.A., Lewin K.J., Longmire Jr W.P. Sclerosing cholangitis and histiocytosis X. Gut. 25:1984;526-530.
187. Leblanc A., Hadchouel M., Jehan P., Odievre M., Alagille D. Obstructive jaundice in children with histiocytosis X. Gastroenterology. 80:1981;134-139.
188. Concepcion W., Esquivel C.O., Terry A., et al. Liver transplantation in Langerhans' cell histiocytosis (histiocytosis X). Semin. Oncol. 18:1991;24-28.
189. Levy J., Espanol-Boren T., Thomas C., et al. Clinical spectrum of X-linked hyper-IgM syndrome. J. Pediat. 131:1997;47-54.
190. Kyokane K., Ichihara T., Horisawa M., et al. Successful treatment of primary sclerosing cholangitis with cyclosporine and corticosteroid. Hepato-Gastroenterology. 41:1994;449-452.
191. Sandborn W.J., Wiesner R.H., Tremaine W.J., Larusso N.F. Ulcerative colitis disease activity following treatment of associated primary sclerosing cholangitis with cyclosporin. Gut. 34:1993;242-246.
192. Van Thiel D.H., Carroll P., Abu-Elmagd K., et al. Tacrolimus (FK 506), a treatment for primary sclerosing cholangitis: results of an open-label preliminary trial. Am. J. Gastroenterol. 90:1995;455-459.
193. Sommerauer J.F., Atkison P., Andrews W., Moore P., Wall W. Liver transplantation for Langerhans' cell histiocytosis and immunomodulation of disease pre- and posttransplant. Transplant. Proc. 26:1994;178-179.
194. Zandi P., Panis Y., Debray D., Bernard D., Houssin D. Pediatric liver transplantation for Langerhans' cell histiocytosis. Hepatology. 21:1995;129-133.
195. Melendez H.V., Dhawan A., Mieli-Vergani G., et al. Liver transplantation for Langerhans' cell histiocytosisa case report and literature review. Transplantation. 62:1996;1167-1171.
196. Mahmoud H., Gaber O., Wang W., Whitington G., Vera S., Murphy S.B. Successful orthotopic liver transplantation in a child with Langerhans cell histiocytosis. Transplantation. 51:1991;278-280.
197. Stieber A.C., Sever C., Starzl T.E. Liver transplantation in patients with Langerhans' cell histiocytosis. Transplantation. 50:1990;338-340.
198. Hunninghake G.W., Kalica A.R. Approaches to the treatment of pulmonary fibrosis. Am. J. Res. Crit. Care Med. 151:1995;915-918.
199. Mapel D.W., Samet J.M., Coultas D.B. Corticosteroids and the treatment of idiopathic pulmonary fibrosis. Past, present, and future. Chest. 110:1996;1058-1067.
200. Unemori E.N., Pickford L.B., Salles A.L., et al. Relaxin induces an extracellular matrix-degrading phenotype in human lung fibroblasts in vitro and inhibits lung fibrosis in a murine model in vivo. J. Clin. Invest. 98:1996;2739-2745.
201. Grois N., Tsunematsu Y., Barkovich A.J., Favara B.E. Central nervous system disease in Langerhans cell histiocytosis. Br. J. CancerSupplement. 23:1994;24-28.
202. Grois N., Barkovich A.J., Rosenau W., Ablin A.R. Central nervous system
203. Grois NG, Favara BE, Mostbeck GH, Prayer D. Central nervous system disease in Langerhans cell histiocytosis. In Egeler RM, D'Angio GJ, eds. Hematology/Oncol Clin North Am 12. Philadelphia, W.B. Saunders, 1998, 287-305.
204. Minehan K.J., Chen M.G., Zimmerman D., Su J.Q., Colby T.V., Shaw E.G. Radiation therapy for diabetes insipidus caused by Langerhans cell histiocytosis. J. Radiat. Oncol. Biol. Phys. 23:1992;519-524.
205. Broadbent V., Pritchard J. Diabetes insipidus associated with Langerhans cell histiocytosis: is it reversible? Med. Pediat. Oncol. 28:1997;289-293.
206. Lilleyman J.S. The treatment of familial erythrophagocytic lymphohistiocytosis. Cancer. 46:1980;468-470.
207. Alvardo C.S., Buchanan G.R., Kim T.H., Zaatari G., Sartain P., Ragab A. Use of VP-16-213 in the treatment of familial erythrophagocytic lymphohistiocytosis. Cancer. 57:1986;1097-2001.
208. Fischer A., Virelizier J.L., Arenzana-Seiwdedos F., Perez N., Nezelof C., Griscelli C. Treatment of four patients with erythrophagocytic lymphohistiocytosis by a combination of epipodophyllotoxin, steroid, intrathecal methotrexate, and cranial irradiation. Pediatrics. 76:1985;263-268.
209. Ambruso D.R., Hays T., Zwartjes W.J., Tubergen D.G., Favara B.E. Successful treatment of lymphohistiocytic reticulosis with phagocytosis with epipodophyllotoxin VP-16-213. Cancer. 45:1980;2516-2520.
210. Henter J-I., Elinder G., Finkel Y., Soder O. Successful induction with chemotherapy including teniposide in familial erythrophagocytic lymphohistiocytosis. Lancet. 13:1986;1402.
211. Loechelt B.J., Egeler M., Filipovich A.H., Jyonouchi H., Shapiro R.S. Immunosuppression: preliminary results of alternative maintenance therapy for familial hemophagocytic lymphohistocytosis (FHL). Med. Pediat. Oncol. 22:1994;325-328.
212. Stephan J.L., Donadieu J., Ledeist F., Blanche S., Griscelli C., Fischer A. Treatment of familial hemophagocytic lymphohistiocytosis with antithymocyte globulins, steroids, and cyclosporin A. Blood. 82:1993;2319-2323.
213. Fischer A., Cerf-Bensussan N., Blanche S., et al. Allogenic bone marrow transplantation for erythrophagocytic lymphohistiocytosis. J. Pediat. 108:1986;267-270.
214. Henter J.I., Arico M., Elinder G., Imashuku S., Janka G. Familial hemophagocytic lymphohistiocytosis. Primary hemophagocytic lymphohistiocytosis. Hemat./Oncol. Clin. North Am. 12:1998;417-433.
215. Blanch S., Caniglia M., Fishcer A., Griscelli C. Treatment of familial lymphohistiocytosis: chemotherapy or bone marrow transplant? Pediat. Hematol. Oncol. 6:1989;273-275.
216. Bolme P., Henter J.I., Winiarski J., et al. Allogeneic bone marrow transplantation for hemophagocytic lymphohistiocytosis in Sweden. Bone Marrow Transplant. 15:1995;331-335.
217. Adachi S., Kubota M., Akiyama Y., Kato T., Kitoh T., Furusho K. Successful bone marrow transplantation from an HLA-identical unrelated donor in a patient with hemophagocytic lymphohistiocytosis. Bone Marrow Transplant. 19:1997;183-185.
218. Baker K.S., DeLaat C.A., Steinbuch M., et al. Successful correction of hemophagocytic lymphohistiocytosis with related or unrelated bone marrow transplantation. Blood. 89:1997;3857-3863.
219. Jabado N., Le Deist F., Cant A., et al. Bone marrow transplantation from genetically HLA-nonidentical donors in children with fatal inherited disorders excluding severe combined immunodeficiencies: use of two monoclonal antibodies to prevent graft rejection. Pediatrics. 98:1996;420-428.
220. Landman-Parker J., Le Deist F., Blaise A., Brison O., Fischer A. Partial engraftment of donor bone marrow cells associated with long-term remission of haemophagocytic lymphohistiocytosis. Br. J. Haematol. 85:1993;37-41.
221. Henter J.I., Arico M., Egeler R.M., et al. HLH-94: a treatment protocol for hemophagocytic lymphohistiocytosis. HLH Study Group of the Histiocyte Society. Med. Pediat. Oncol. 28:1997;342-347.
222. Simms S, Warner NJ. A framework for understanding and responding to the psychosocial needs of children with Langerhans cell histiocytosis and their families. In Egeler RM, D'Angio GJ, eds. Hemat/Oncol Clin North Am 12. Philadelphia, W.B. Saunders, 1998, 359-367.
223. Shuper A., Attias D., Kornreich L., Zaizov R., Yaniv I. Familial hemophagocytic lymphohistiocytosis: improved neurodevelopmental outcome after bone marrow transplantation. J. Pediat. 133:1998;126-128.
224. Kelly K.M., Beverley P.C., Chu A.C., et al. Successful in vivo immunolocalization of Langerhans cell histiocytosis with use of a monoclonal antibody, NA1/34. J. Pediat. 125:1994;717-722.
225. Kelly K.M., Pritchard J. Monoclonal antibody therapy in Langerhans cell histiocytosisfeasible and reasonable? Br. J. CancerSuppl. 23:1994;S54-S55.
226. Schmitz L., Favara B.E. Nosology and pathology of Langerhans cell histiocytosis. Hemat. Oncol. Clin. North Am. 12:1998;221-246.
227. Faigle W., Raposo G., Tenza D., et al. Deficient peptide loading and MHC class II endosomal sorting in a human genetic immunodeficiency disease: the Chediak-Higashi syndrome. J. Cell Biol. 141:1998;1121-1134.
228. Misumi D.J., Nagle D.L., McGrail S.H., et al. The physical and genetic map surrounding the Lyst gene on mouse chromosome 13. Genomics. 40:1997;147-150.
229. Pastural E., Barrat F.J., Dufourcq-Lagelouse R., et al. Griscelli disease maps to chromosome 15q21 and is associated with mutations in the myosin-Va gene. Nat. Genet. 16:1997;289-292.
230. Coffey A., Brooksbank R., Brandau O., et al. Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene. Nature Genet. 20:1998;129-135.
231. Sayos J., Wu C., Morra M., et al. The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM. Nature. 395:1998;462-469.